Excipients labelling

The European Medicines Agency (EMA) publishes information on excipients for inclusion in the labelling and package leaflet of human medicines.

An excipient is a constituent of a medicine other than the active substance, added in the formulation for a specific purpose.

Marketing authorisation holders and applicants are required to list excipients on the medicine's labelling according to the European Commission guideline pursuant to Article 65 of Directive 2001/83/EC.

The European Commission's Notice to Applicants Group has adopted a revised guideline on excipients labelling, following a targeted stakeholder consultation carried out by the European Commission. The revised guideline includes a timeline for the implementation of its annex and updated explanatory notes. The Commission published the revised guideline in March 2018:

According to Directive 2001/83/EC, all excipients in parenteral, ocular and topical medicines, as well as the excipients listed in the annex to the guideline, must appear on the labelling.

In addition, all excipients listed in the annex must be included in the package leaflet together with the relevant information set out in the annex.

Annex to the European Commission guideline

The annex contains a list of all excipients known to have a recognised action or effect that need to be displayed on the label of any medicine authorised in the European Union (EU):

EMA's Excipients Drafting Group (ExcpDG) reviews the annex regularly to update the information on excipients or include new excipients.

Update: EMA published a new version of the updated annex in November 2019, after a public consultation for each excipient, adoption by EMA's Committee for Medicinal Products for Human Use (CHMP) and endorsement by the European Commission's Notice to Applicants Group.

The annex is effective from its date of publication.

For already authorised medicines, marketing authorisation holders should use the first opportunity to implement the wording in compliance with the revised annex.

For medicines with no foreseeable regulatory submissions, marketing authorisation holders should submit a type IB variation within 3 years after the publication of the revised annex.

List of updated excipients and background reviews

The ExcpDG prepares a report on each excipient under review, containing a scientific background review and the updated information for the package leaflet.

All excipient documents can be found in the list below.


How useful was this page?

Add your rating
2 ratings
2 ratings
1 rating
7 ratings